Agape ATP (NASDAQ:ATPC) Stock Price Down 3% - Time to Sell?

Key Points

• Agape ATP Corporation shares fell by 3%, trading at $1.28, with a total volume decline of 4% from the average session.
• Despite the recent drop, analysts at Wall Street Zen upgraded the stock from a "sell" rating to a "hold" rating, indicating potential growth.
• The company reported a negative net margin of 183.13% and a P/E ratio of -3.12 in its latest earnings results.

Shares of Agape ATP Corporation (NASDAQ:ATPC - Get Free Report) traded down 3% during trading on Monday . The company traded as low as $1.28 and last traded at $1.28. 28,738 shares changed hands during trading, a decline of 4% from the average session volume of 30,067 shares. The stock had previously closed at $1.32.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Agape ATP from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd.

Agape ATP Price Performance

The stock has a market capitalization of $64.01 million, a price-to-earnings ratio of -3.12 and a beta of -0.98. The firm's fifty day moving average is $1.34 and its 200-day moving average is $1.48.

Agape ATP (NASDAQ:ATPC - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.01) earnings per share for the quarter. Agape ATP had a negative net margin of 183.13% and a negative return on equity of 20.32%.

About Agape ATP

Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.